GlassScriptPhysician profile
Julie K Tran
NPI 1750589412
$2,547.25
in general payments reported to CMS, 2019-2025
15 companies · $242 in 2025
The $242 reported for 2025 was more than what 84% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $563 · 2020: $484 · 2021: $731 · 2022: $279 · 2023: $79.45 · 2024: $168 · 2025: $242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $490.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $489.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $926.22 | 2019-2023 | Proclaim, Eterna |
| Boston Scientific Corporation | $857.30 | 2020-2022 | |
| Tersera Therapeutics LLC | $200.92 | 2019 | |
| Janssen Biotech, INC. | $150.47 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $86.73 | 2024-2025 | Dupixent |
| Abbvie INC. | $61.57 | 2019-2025 | |
| Madrigal Pharmaceuticals | $49.23 | 2024 | Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $37.66 | 2023-2025 | Entyvio |
| Qol Medical, LLC | $34.68 | 2025 | Sucraid |
| Medtronic, INC. | $34.33 | 2023-2024 | Intellis Adaptivestim |
| Phathom Pharmaceuticals, INC. | $29.01 | 2025 | Voquezna |
| Vivus LLC | $24.84 | 2025 | Pancreaze |
| Pacira Pharmaceuticals Incorporated | $23.19 | 2025 | Exparel |
| Painteq LLC | $15.75 | 2024 | Painteq |
| Nevro Corp. | $15.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.